Prevention of emergence cough after general anesthesia with intravenous dexmedetomidine (0.5 microgram per kilogram) and intracuff ropivacaine 0.2 percentage

Intracuff Ropivacaine 0.2 percentage and Intravenous Dexmedetomidine (0.5 microgram per kilogram) for prevention of emergence cough after General Anaesthesia - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076676

Enrollment

Registered

2024-11-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group-Ropivacaine and dexmedetomidine: Single dose of Intravenous dexmedetomidine at the dose of 0.5mcg/kg, diluted upto 10ml given as infusion,10minutes before intubation. During intub

Eligibility

Inclusion criteria

Inclusion criteria: -Age group between 18-60years of either sex -Patient belonging to American Society of Anaesthesiologist Physical status1&2.

Exclusion criteria

Exclusion criteria: Patient Refusal ASA Grade 3 and 4 Allergy to local anaesthetics Obesity(BMI more than 30) Raised ICP Cervical spine,oral and maxillofacial surgeries History of previous laryngeal,tracheal surgery or pathology

Design outcomes

Primary

Measure	Time frame
Effect of study drugs in decreasing the incidence of emergence cougingTimepoint: 30mins post extubation	—

Secondary

Measure	Time frame
Effect of study drugs on hemodynamics,Cough,post operative sore throat,Horaseness and ECG changesTimepoint: 24hrs	—

Countries

India

Contacts

Public ContactDr Rajeev Kumar Dubey

INSTITUTE OF MEDICAL SCIENCES,BANARAS HINDU UNIVERSITY

rajeevdubeyrk@gmail.com9839927283

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026